All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

First-line Cemiplimab Plus Chemo Wins Approval in Canada for Advanced NSCLC

May 2nd 2023

Health Canada has approved the combination of cemiplimab and platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic non–small cell lung cancer without EGFR, ALK, or ROS1 aberrations who are not candidates for definitive chemoradiation.

Key Trial Updates Confirm and Clarify Treatment Approaches Across Genitourinary Cancers

May 2nd 2023

Matthew Galsky, MD, highlights updates in metastatic urothelial cancer treatment, as well as the evolution of PARP inhibitors and the optimal use of intensified triplet therapy in prostate cancer.

CLDN18.2 Testing May Influence Advances in the Gastric Cancer Treatment Paradigm

May 2nd 2023

Kevin M. Waters, MD, PhD, discusses key findings from a study that reinforced the rationale for Claudin18.2 testing, the prevalence of this protein in gastric cancers, and how this potential therapeutic target represents the evolving role of pathology in cancer diagnosis and care.

Researcher at Lewis Katz School of Medicine and Fox Chase Wins $800,000 Grant for Work on Childhood Cancers

May 1st 2023

Christian Hurtz, PhD, an assistant professor at the Fels Cancer Institute for Personalized Medicine at the Lewis Katz School of Medicine at Temple University, has been awarded a four-year $800,000 A-Award by Alex’s Lemonade Stand Foundation for Childhood Cancer.

Liso-cel Induces Statistically Significant Responses in R/R Follicular Lymphoma and Mantle Cell Lymphoma

May 1st 2023

Lisocabtagene maraleucel elicited statistically significant and clinically meaningful responses in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma, meeting the primary end point of the phase 2 TRANSCEND FL and phase 1 TRANSCEND NHL 001 trials, respectively.

FDA Grants Regular Approval to Cemiplimab for Metastatic Basal Cell Carcinoma

May 1st 2023

The FDA has granted full approval to cemiplimab-rwlc for the treatment of patients with metastatic basal cell carcinoma who previously received a hedgehog inhibitor (HHI) or for whom a HHI is not appropriate.

FDA Grants Priority Review to Luspatercept for First-line Treatment of Anemia in Lower-risk MDS

May 1st 2023

The FDA has granted a priority review to the supplemental biologics license application seeking to expand the current indication of luspatercept to include treatment of anemia in patients with very low- to intermediate-risk myelodysplastic syndrome who have not previously received erythropoiesis-stimulating agents and who may require red blood cell transfusions.

Pembrolizumab Monotherapy Demonstrates Clinical Efficacy in High-risk NMIBC

May 1st 2023

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.

TAR-200 Produces High CR Rates, Tolerability in BCG-unresponsive NMIBC

May 1st 2023

Treatment with TAR-200 produced complete responses and was well tolerated in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, according to preliminary data from the phase 2b SunRISe-1 trial.

FDA Approves xT CDx, a NGS-Based in Vitro Diagnostic Device

May 1st 2023

The FDA has approved xT CDx, a 648-gene next-generation sequencing assay for solid tumor profiling, and companion diagnostic for patients with colorectal cancer.

Nivolumab Maintains DFS Benefit in MIUC and MIBC After Radical Surgery

May 1st 2023

Nivolumab following radical surgery continued to display a benefit in disease-free survival in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.

Sintilimab Plus Axitinib Has Clinical Efficacy in Advanced FH-Deficient RCC

April 30th 2023

Treatment with sintilimab in combination with axitinib resulted in tumor shrinkage with tolerable adverse effects in patients with advanced fumarate hydratase–deficient renal cell carcinoma.

Complications Following Partial Nephrectomy Associated With Particular Comorbidities in RCC

April 30th 2023

Specific comorbidities were linked with complications following partial nephrectomy, compared with radical nephrectomy, in patients with T1b to T2 renal cell carcinoma.

Hypertension Linked With Worse Outcomes for Patients With Upper Tract Urothelial Cancer Undergoing Nephroureterectomy

April 30th 2023

Hypertension was found to be an independent risk factor for worse survival outcomes in patients with upper tract urothelial cancer undergoing radical nephroureterectomy.

High BMI Associated With Longer OS in Patients With RCC Undergoing Nephrectomy

April 30th 2023

A high body mass index was linked with improved overall survival in patients with renal cell carcinoma undergoing radical nephrectomy.

Dr Lowentritt on PSA Response and Time to Castration Resistance in mCSPC

April 29th 2023

Benjamin H. Lowentritt, MD, FACS, discusses prostate-specific antigen response and time to castration resistance in patients with metastatic castration-sensitive prostate cancer started on apalutamide, enzalutamide, or abiraterone acetate.

Enzalutamide With or Without Leuprolide Offers MFS Benefit Vs Leuprolide Alone in nmHSPC With High-risk BCR

April 29th 2023

Treatment with the androgen receptor inhibitor enzalutamide plus leuprolide led to a significant reduction in the risk of metastasis or death compared with placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Apalutamide Demonstrates Robust Real-World Effectiveness in mCSPC

April 29th 2023

Patients with metastatic castration-sensitive prostate cancer treated with the androgen receptor–signaling inhibitor apalutamide achieved prostate-specific antigen responses that trended higher and rates of progression to castration resistance that trended lower than those receiving enzalutamide or abiraterone acetate/

Darolutamide Plus ADT/Docetaxel Produces Durable PSA Responses in mHSPC

April 29th 2023

A post-hoc analysis of the phase 3 ARASENS trial demonstrated that the addition of darolutamide to androgen deprivation therapy and docetaxel produced deep and durable prostate-specific antigen responses in patients with metastatic hormone-sensitive prostate cancer.

Darolutamide Plus ADT Elicits OS Benefit in North American Patients With mHSPC

April 29th 2023

A subgroup analysis of the phase 3 ARASENS trial showed that darolutamide plus androgen deprivation therapy elicited an overall survival benefit in North American patients with metastatic hormone-sensitive prostate cancer.